The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy

Figure 6

Inhibition of RAC1 blocks glycolysis. (a). RNA-seq analysis represented by a heatmap of gene expression for glycolysis in HCC cells after treatment with Sorafenib, EHop-016 (EHOP), or combination therapy (Sorafenib and EHop) (Figures (b)&(c). The expression of glycolytic enzymes PKM, LDHA, ALDOA, and HK1 was examined using the western blot. (d). Glucose consumption in HCC cells after being treated with Sorafenib, EHop-016, or combination therapy. (e). Lactate production of HCC cells was measured under the treatment of Sorafenib, EHop-016, or combination therapy. (f). Glucose uptake was determined after HCC cells were treated with Sorafenib, EHop-016, or combination therapy. (g). ATP production in HCC cells that were treated with Sorafenib, EHop-016, or combination therapy. . Statistical differences were analyzed using Student’s t-tests. Error bars represent SEM from triplicate experiments.

(a)

(b)

(c)

(d)

(e)

(f)

(g)